Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2016 > Volume 25 Number 4 July 2016 > LETTERS TO THE EDITOR > The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis

The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis

Alberto Banzato1, Gentian Denas2,4, Giuseppe Lombardi3, Ardi Pambuku3, Alessandra Bianchi1, Vittorio Pengo2

1Cardiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
2Cardiology Clinic, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy
3Medical Oncology 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
4Electrronic correspondence: gentian.denas@unipd.it

Letter to the Editor

Patients with a mechanical heart prosthesis require lifelong anticoagulation to prevent valve thrombosis that could lead to deleterious complications or even death. LMWH protocols have proven feasible and safe in most mechanical prosthesis bearers requiring an interruption of oral anticoagulation because of surgery. However, some patient populations have not been included in trials and might behave differently. To this end, we would like to present the case of a 56-year-old man with mechanical aortic prosthesis treated with bevacizumab. His past

medical history included aortic valve substitution for aortic stenosis, with a mechanical prosthesis, brain surgery for the excision of a single brain metastasis, and chemotherapy. In such a complicated scenery the choice of antithrombotic management in heart valvebearers should be individually tailored, taking into consideration the patient and antineoplastic therapy characteristics. Given the lack of evidence and of specific guidelines, patients with a mechanical heart valve should receive a strict control to avoid thrombotic complications.

The Journal of Heart Valve Disease 2016;25:522-524


The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.